

2024 American Society of
Hematology Annual Conference

Servier Pharmaceuticals Sponsored Abstracts

ABSTRACTS

2024 American Society of Hematology Annual Conference

SERVIER 

For full abstracts please visit the **ASH website**

| Date & Time | Title | Presentation |
|---|--|--|
| Sun December 8, 2024 6:00 – 8:00 p.m. | Outcomes by frailty in IC-ineligible newly diagnosed AML – a real-world evidence comparison by treatment with hypomethylating agents + ivosidenib or venetoclax. | Poster Presentation <u>B. Douglas Smith</u> Sidney Kimmel Cancer Center, Johns Hopkins University |
| Sun December 8, 2024 6:00 – 8:00 p.m. | Improved Hematologic Recovery with Ivosidenib in Patients with mIDH1 Relapsed or Refractory MDS: Results from a Phase 1 Substudy. | Poster Presentation <u>Praneeth Baratam</u> Hollings Cancer Center, Medical University of South Carolina |
| Mon December 9, 2024 6:00 – 8:00 p.m. | Indirect treatment comparison of ivosidenib and other therapies in patients with newly diagnosed acute myeloid leukemia. | Poster Presentation <u>Manuel David Gil-Sierra</u> University of Sevilla |
| Sat December 7, 2024 5:30 – 7:30 p.m. | Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (mIDH1) Relapsed/Refractory Myelodysplastic Syndrome: Update of the Phase 1 Substudy According to the International Working Group 2023 Criteria. | Poster Presentation <u>Yazan F. Madanat</u> UT Southwestern Medical Center |
| Sat December 7, 2024 10:30 a.m. | Challenges in Leukemia Diagnosis and Treatment in Mexico: A Survey by the Alliance for Leukemias in Mexico on Resource Availability, Infrastructure, and Access to Advanced Therapies for Leukemia Patients. | Oral Presentation <u>Roberta Demichelis-Gómez</u> Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán |
| Sat December 7, 2024 5:30 – 7:30 p.m. | S227928: A Novel Anti-CD74 ADC with MCL-1 Inhibitor Payload for the Treatment of Acute Myeloid Leukemia (AML) and Other Hematologic Malignancies. | Poster Presentation <u>Ana Leticia Maragno</u> Institut de Recherches, Servier (France) |
| Sat December 7, 2024 5:30 – 7:30 p.m. | Mutant IDH1 blocks neutrophil maturation by repressing myeloid progenitor programs. | Poster Presentation <u>Mariam Hakobyan</u> German Cancer Research Center (DKFZ) |
| Sat December 7, 2024 5:30 – 7:30 p.m. | Phase 3 Study of Either Ivosidenib (IVO) Monotherapy or Azacitidine (AZA) Monotherapy in Patients with IDH1 Mutant Myelodysplastic Syndromes (MDS) Who Are Hypomethylating Agent (HMA) Naïve (PyramIDH) | Poster Presentation <u>Marie Sebert</u> Hôpital Saint-Louis |